Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: A systematic review and network metaanalysis

Journal of Rheumatology

Volumn 41, Issue 10, 2014, Pages 1998-2007

  Tian, Simon Yu ^a,b   Feldman, Brian M ^b,c   Beyene, Joseph ^a,d   Brown, Patrick E ^a,d,e   Uleryk, Elizabeth M ^b   Silverman, Earl D ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e CANCER CARE ONTARIO   (Canada)

Author keywords

Clinical trials; Drug therapy; Immunosuppressive agents; Lupus nephritis; Metaanalysis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROLIFERATIVE LUPUS NEPHRITIS; PROTEINURIA; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RENAL REMISSION; SENSITIVITY ANALYSIS; TREATMENT DURATION; ANALOGS AND DERIVATIVES; LUPUS NEPHRITIS; PROCEDURES; TREATMENT OUTCOME;

AZATHIOPRINE; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PREDNISONE; REMISSION INDUCTION; TACROLIMUS; TREATMENT OUTCOME;

EID: 84924790872     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140050     Document Type: Article

References (39)

1. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538-46.
2. van Tellingen A, Voskuyl AE, Vervloet MG, Bijl M, de Sévaux RG, Berger SP, et al; Dutch Working Party on Systemic Lupus Erythematosus. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med 2012;70:199-206.
3. Mosca M, Bencivelli W, Neri R, Pasquariello A, Batini V, Puccini R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002;61:1502-9.
4. Benseler SM, Bargman JM, Feldman BM, Tyrrell PN, Harvey E, Hebert D, et al. Acute renal failure in paediatric systemic lupus erythematosus: treatment and outcome. Rheumatology 2009;48:176-82.
5. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797-808.
6. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
7. Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis. Am J Kidney Dis 2013;62:403-41.
8. El-Sehemy MS, Al-Saaran AM, Baddour NM, Adam AG, Moez PE. Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis. Egypt J Immunol 2006;13:39-52.
9. Li X, Ren H, Zhang Q, Zhang W, Wu X, Xu Y, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant 2012;27:1467-72.
10. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004;43:197-208.
11. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
12. Korbet SM, Lewis EJ; Collaborative Study Group. Severe lupus nephritis: the predictive value of a ≥ 50% reduction in proteinuria at 6 months. Nephrol Dial Transplant 2013;28:2313-8.
13. Ades AE, Madan J, Welton NJ. Indirect and mixed treatment comparisons in arthritis research. Rheumatology 2011;50:iv5-9.
14. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular diseases. Tokyo: Igaku-Shoin; 1982.
15. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. [Internet. Accessed June 6, 2014.] Available from: www.cochrane-handbook.org.
17. Donadio Jr JV, Holley KE, Ferguson RH, Ilstrup DM. Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide. Mayo Clin Proc 1976;51:484-94.
18. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
19. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84.
20. Chen W, Tang X, Liu Q, Chen W, Fu P, Liu F, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44.
21. Donadio Jr JV, Holley KE, Wagoner RD, Ferguson RH, McDuffie FC. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 1972;77:829-35.
22. El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol 2010;14:214-21.
23. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
24. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Ann Intern Med 1975;83:597-605.
25. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009;19:606-15.
26. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005;10:504-10.
27. Ren H, Yu H, Wang X, Hao G, Chen N. A preliminary study of tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis [CCTR abstract]. Nephrol Dial Transplant 2007;22:vi276.
28. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester, UK: John Wiley & Sons; 2004.
29. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network-meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011;14:417-28.
30. Multi-parameter evidence synthesis (MPES) programme. Mixed treatment comparisons. Bristol, Avon, UK: University of Bristol; 2012. [Internet. Accessed June 6, 2014.] Available from: www.bristol.ac.uk/social-community-medicine/projects/mpes/mtc
31. Ades AE, Mavranezouli I, Dias S, Welton NJ, Whittington C, Kendall T. Network meta-analysis. Lawrenceville, NJ: International Society for Pharmacoeconomics and Outcomes Research; 2013:505.
32. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011;14:429-37.
33. Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 1974;17:923-37.
34. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis. Cochrane Database Syst Rev 2004(1):CD002922.
35. Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006;82:368-74.
36. van Vollenhoven RF. Challenges and opportunities in SLE clinical trials. Curr Opin Rheumatol 2013;25:606-15.
37. Wofsy D, Hillson JL, Diamond B. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 2013;65:1586-91.
38. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1373-9.
39. Bozzolo EP, Ramirez GA, Bonavida G, Lanzani C, Scotti R, Dell'Antonio G, et al. Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. Autoimmunity 2013;46:537-46.